Top

Published in:

01-04-2017 | Original Paper

PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis

Authors: Julia Alejandra Pezuk, María Sol Brassesco, Ricardo Santos de Oliveira, Hélio Rubens Machado, Luciano Neder, Carlos Alberto Scrideli, Luiz Gonzaga Tone

Published in: Child's Nervous System | Issue 4/2017

Abstract

Purpose

Medulloblastoma (MB) is the most common malignant tumor of the central nervous system (CNS) in children. Despite its relative good survival rates, treatment can cause long time sequels and may impair patients’ lifespan and quality, making the search for new treatment options still necessary. Polo like kinases (PLKs) constitute a five-member serine/threonine kinases family (PLK 1–5) that regulates different stages during cell cycle. Abnormal PLKs expression has been observed in several cancer types, including MB. As gene regulators, miRNAs have also been described with variable expression in cancer.

Methods

We evaluated gene expression profiles of all PLK family members and related miRNAs (miR-100, miR-126, miR-219, and miR-593*) in MB cell lines and tumor samples.

Results

RT-qPCR analysis revealed increased levels of PLK1–4 in all cell lines and in most MB samples, while PLK5 was found underexpressed. In parallel, miR-100 was also found upregulated while miR-129, miR-216, and miR-593* were decreased in MB cell lines. Variable miRNAs expression patterns were observed in MB samples. However, a correlation between miR-100 and PLK4 expression was observed, and associations between miR-100, miR-126, and miR-219 expression and overall and event free survival were also evinced in our cohort. Moreover, despite the lack of association with clinico-pathological features, when comparing primary tumors to those relapsed, we found a consistent decrease on PLK2, miR-219, and miR-598* and an increase on miR-100 and miR-126.

Conclusion

Specific dysregulation on PLKs and associated miRNAs may be important in MB and can be used to predict prognosis. Although miRNAs sequences are fundamental to predict its target, the cell type may also be consider once that mRNA repertoire can define different roles for specific miRNA in a given cell.

Available only for authorised users

Bihannic L, Ayrault O (2016) Insights into cerebellar development and medulloblastoma. Bull Cancer 103:30–40. doi:10.1016/j.bulcan.2015.11.002 CrossRefPubMed

Sadighi Z, Vats T, Khatua S (2012) Childhood medulloblastoma: the paradigm shift in molecular stratification and treatment profile. J Child Neurol 27:1302–1307. doi:10.1177/0883073812449690 CrossRefPubMed

Kijima N, Kanemura Y (2016) Molecular classification of medulloblastoma. Neurol Med Chir (Tokyo). doi:10.2176/nmc.ra.2016-0016

Crawford JR, MacDonald TJ, Packer RJ (2007) Medulloblastoma in childhood: new biological advances. Lancet Neurol 6:1073–1085. doi:10.1016/S1474-4422(07)70289-2 CrossRefPubMed

Remke M, Ramaswamy V, Taylor MD (2013) Medulloblastoma molecular dissection: the way toward targeted therapy. Curr Opin Oncol 25:674–681. doi:10.1097/CCO.0000000000000008 CrossRefPubMed

Vaid R, Sharma N, Chauhan S et al (2016) Functions of polo-like kinases: a journey from yeast to humans. Protein Pept Lett 23:185–197CrossRefPubMed

Johnson EF, Stewart KD, Woods KW et al (2007) Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry 46:9551–9563. doi:10.1021/bi7008745 CrossRefPubMed

De Falco M, De Luca A (2010) Cell cycle as a target of antineoplastic drugs. Curr Pharm Des 16:1417–1426CrossRefPubMed

Palmisiano ND, Kasner MT (2015) Polo-like kinase and its inhibitors: ready for the match to start? Am J Hematol 90:1071–1076. doi:10.1002/ajh.24177 CrossRefPubMed

10.

Pezuk JA, Brassesco MS, Morales AG et al (2013) Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation. Cancer Biother Radiopharm 28:516–522. doi:10.1089/cbr.2012.1415 CrossRefPubMedPubMedCentral

11.

de Oliveira JC, Brassesco MS, Pezuk JA et al (2012) In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. J Drugs Dermatol 11:587–592PubMed

12.

Liu Z, Sun Q, Wang X (2017) PLK1, a potential target for cancer therapy. Transl Oncol 10:22–32. doi:10.1016/j.tranon.2016.10.003 CrossRefPubMed

13.

Harris PS, Venkataraman S, Alimova I et al (2012) Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 12:80. doi:10.1186/1471-2407-12-80 CrossRefPubMedPubMedCentral

14.

Guerreiro AS, Fattet S, Kulesza DW et al (2011) A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res 9:925–935. doi:10.1158/1541-7786.MCR-10-0200 CrossRefPubMed

15.

Winkles JA, Alberts GF (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24:260–266. doi:10.1038/sj.onc.1208219 CrossRefPubMed

16.

Petrelli A, Perra A, Schernhuber K et al (2012) Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene 31:4517–4526. doi:10.1038/onc.2011.631 CrossRefPubMed

17.

Ito T, Sato F, Kan T et al (2011) Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer. Int J Cancer 129:2134–2146. doi:10.1002/ijc.25874 CrossRefPubMedPubMedCentral

18.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408. doi:10.1006/meth.2001.1262 CrossRefPubMed

19.

Taylor MD, Northcott PA, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465–472. doi:10.1007/s00401-011-0922-z CrossRefPubMed

20.

Degenhardt Y, Lampkin T (2010) Targeting polo-like kinase in cancer therapy. Clin Cancer Res 16:384–389. doi:10.1158/1078-0432.CCR-09-1380 CrossRefPubMed

21.

Guan R, Tapang P, Leverson JD et al (2005) Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65:2698–2704. doi:10.1158/0008-5472.CAN-04-2131 CrossRefPubMed

22.

Pellegrino R, Calvisi DF, Ladu S et al (2010) Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 51:857–868. doi:10.1002/hep.23467 PubMed

23.

Schmit TL, Ledesma MC, Ahmad N (2010) Modulating polo-like kinase 1 as a means for cancer chemoprevention. Pharm Res 27:989–998. doi:10.1007/s11095-010-0051-8 CrossRefPubMedPubMedCentral

24.

Triscott J, Lee C, Foster C et al (2013) Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children. Cancer Res 73:6734–6744. doi:10.1158/0008-5472.CAN-12-4331 CrossRefPubMed

25.

Ou B, Zhao J, Guan S et al (2016) Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/cyclin E in colorectal cancer. Cancer Lett 380:457–466. doi:10.1016/j.canlet.2016.07.004 CrossRefPubMed

26.

Cizmecioglu O, Warnke S, Arnold M et al (2008) Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell Cycle 7:3548–3555CrossRefPubMed

27.

Archambault V, Glover DM (2009) Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10:265–275. doi:10.1038/nrm2653 CrossRefPubMed

28.

Yang Y, Bai J, Shen R et al (2008) Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 68:4077–4085. doi:10.1158/0008-5472.CAN-07-6182 CrossRefPubMedPubMedCentral

29.

Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643–660. doi:10.1038/nrd3184 CrossRefPubMed

30.

de Cárcer G, Escobar B, Higuero AM et al (2011a) Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol 31:1225–1239. doi:10.1128/MCB.00607-10 CrossRefPubMedPubMedCentral

31.

de Cárcer G, Manning G, Malumbres M (2011b) From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 10:2255–2262. doi:10.4161/cc.10.14.16494 CrossRefPubMedPubMedCentral

32.

Voorhoeve PM, Agami R (2007) Classifying microRNAs in cancer: the good, the bad and the ugly. Biochim Biophys Acta - Rev Cancer 1775:274–282. doi:10.1016/j.bbcan.2006.11.003 CrossRef

33.

Kozomara A, Griffiths-Jones S (2014) MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42:68–73. doi:10.1093/nar/gkt1181 CrossRef

34.

Chou C-H, Chang N-W, Shrestha S et al (2016) miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44:D239–D247. doi:10.1093/nar/gkv1258 CrossRefPubMed

35.

Sarachana T, Zhou R, Chen G, et al (2010) Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profi ling of lymphoblastoid cell lines.

36.

Shi W, Alajez NM, Bastianutto C et al (2010) Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer 126:2036–2048. doi:10.1002/ijc.24880 PubMed

37.

Zhao L-L, Jin F, Ye X et al (2015) Expression profiles of miRNAs and involvement of miR-100 and miR-34 in regulation of cell cycle arrest in Artemia. Biochem J 470:223–231. doi:10.1042/BJ20150116 CrossRefPubMed

38.

Li BH, Zhou JS, Ye F et al (2011) Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein. Eur J Cancer 47:2166–2174. doi:10.1016/j.ejca.2011.04.037 CrossRefPubMed

39.

Li Z, Lu J, Sun M et al (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 105:15535–15540. doi:10.1073/pnas.0808266105 CrossRefPubMedPubMedCentral

40.

Ishizaki T, Tamiya T, Taniguchi K et al (2011) miR126 positively regulates mast cell proliferation and cytokine production through suppressing Spred1. Genes Cells 16:803–814. doi:10.1111/j.1365-2443.2011.01529.x CrossRefPubMed

41.

Yang S, Li Y, Gao J et al (2013) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene 32:4294–4303. doi:10.1038/onc.2012.432 CrossRefPubMed

42.

Crawford M, Brawner E, Batte K et al (2008) MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373:607–612. doi:10.1016/j.bbrc.2008.06.090 CrossRefPubMed

Title: PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis
Authors: Julia Alejandra Pezuk
María Sol Brassesco
Ricardo Santos de Oliveira
Hélio Rubens Machado
Luciano Neder
Carlos Alberto Scrideli
Luiz Gonzaga Tone
Publication date: 01-04-2017
Publisher: Springer Berlin Heidelberg
Published in: Child's Nervous System / Issue 4/2017
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI: https://doi.org/10.1007/s00381-017-3366-5

At a glance: The STEP trials

Springer Medicine

PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2017

Association of evening smartphone use with cardiac autonomic nervous activity after awakening in adolescents living in high school dormitories

Multiple neural tube defects: a rare combination of limited dorsal myeloschisis, diplomyelia with dorsal bony spur, sacral meningocoele, syringohydromyelia, and tethered cord

Considerations in deep brain stimulation (DBS) for pediatric secondary dystonia

Bone mineral density and insulin-like growth factor-1 in children with spastic cerebral palsy

Children presenting in delayed fashion after minor head trauma with scalp swelling: do they require further workup?

Frontal burr hole approach for neuroendoscopic resection of craniopharyngioma with the NICO Myriad device: report of two cases